Subtype
Urothelial Neoplasm
CI-CAN-00001629Explore in graph →
Non-malignant237 active trials5 approved drugs8 evidence items
- NCIt
- C39852
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001629Explore in graph →
Clinical trials
626 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07390617 | A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma | recruiting | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 |
| NCT07386847 | A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer | completed | — | 1 | PfizerINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT03291028 | Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma | active not recruiting | — | 15 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04216290 | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial | active not recruiting | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 22, 2026 | clinicaltrials |
| NCT07602010 | Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging | recruiting | — | 150 | Oslo University HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | active not recruiting | Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06204614 | Drug Screening Using IMD in Bladder Cancer | enrolling by invitation | Early Phase 1 | 18 | Brigham and Women's HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07591805 | HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC(HERO-UTUC) | not yet recruiting | Phase 2 | 49 | RenJi HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | recruiting | Phase 1 | 158 | Avacta Life Sciences LtdINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03601455 | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | active not recruiting | Phase 2 | 13 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05243550 | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer(ENVISION) | active not recruiting | Phase 3 | 240 | UroGen Pharma Ltd.INDUSTRY | 10 | May 11, 2026 | clinicaltrials |
| NCT05661955 | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT06318871 | Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | active not recruiting | Early Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04146064 | Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response | completed | — | 190 | University Health Network, TorontoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07087860 | Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers(RECIPE-B1) | recruiting | Phase 2 | 70 | Mayo ClinicOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05154994 | Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma(RESOLVE) | active not recruiting | Phase 1 | 9 | University of UtahOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07231809 | Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients(HIVEC) | not yet recruiting | N/A | 50 | AC.TA. S.r.l.INDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06335667 | mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer | recruiting | N/A | 30 | University of California, IrvineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05646485 | Bladder Cancer Screening Trial | recruiting | N/A | 1,000 | University of Texas Southwestern Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05946993 | Linking In With Advice and Supports for Men Impacted by Metastatic Cancer(LIAM Mc) | active not recruiting | N/A | 72 | University College CorkOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06682728 | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence | recruiting | Phase 2 | 23 | University of California, IrvineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07241793 | Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)(TRAIN-UC-01) | recruiting | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07413523 | Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA(ASTRA) | recruiting | N/A | 44 | Istituto Clinico HumanitasOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04878029 | Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 1 | 32 | Emory UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07555769 | Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial(CALCIFER) | not yet recruiting | Phase 1 | 20 | Juan Luis VásquezOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT04943380 | Efficacy and Utility of Cxbladder Tests in Hematuria Patients(DRIVE) | completed | — | 682 | Pacific Edge LimitedINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07353294 | Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC | enrolling by invitation | Phase 1 | 12 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05700227 | Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer(ARTIA-Bladder) | terminated | N/A | 2 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06857175 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) | recruiting | Phase 3 | 508 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | terminated | Phase 1 | 21 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07322263 | Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC | recruiting | Phase 2 | 174 | Michael A. O'DonnellOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04693377 | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial | recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04953104 | ARID1A and/or KDM6A Mutation and CXCL13 Expression | active not recruiting | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03609216 | Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | active not recruiting | Phase 2 | 237 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07525349 | Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer | not yet recruiting | — | 100 | Assiut UniversityOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07526792 | SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | not yet recruiting | Phase 3 | 406 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05406713 | Pembrolizumab in Muscle-invasive Bladder Cancer | active not recruiting | Phase 2 | 46 | Matthew GalskyOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02845323 | Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder | active not recruiting | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04822350 | A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA(AVENANCE) | completed | — | 596 | PfizerINDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05226117 | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | completed | Phase 2 | 44 | IRCCS San RaffaeleOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07492225 | Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial | active not recruiting | Phase 2 | 120 | Changhai HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492628 | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma(DUET-UC-NK) | recruiting | Phase 1 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03091660 | S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer | active not recruiting | Phase 3 | 1,000 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04113603 | Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography | active not recruiting | N/A | 352 | Chang Gung Memorial HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 29, 2026source: clinicaltrials